Company Encyclopedia
View More
name
Sirnaomics
02257.HK
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases.
1.296 T
02257.HKMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking37/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE575.13%A
    • Profit Margin-1476.92%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY38.86%A
    • Net Profit YoY82.93%A
    • Total Assets YoY-38.05%E
    • Net Assets YoY-7.68%D
  • Cash ScoreB
    • Cash Flow Margin-6.77%D
    • OCF YoY38.86%A
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreE
    • Gearing Ratio189.65%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Hong Kong Stocks" The Hang Seng Index continued to decline by 215 points in the first half of the day, with domestic property, self-driving, Xinyi-related, and new consumption stocks under pressure, while Chinese biotech stocks rose against the trend

    The Hang Seng Index fell 215 points in the half-day session, with domestic property, self-driving, Xinyi-related, and new consumption stocks under pressure. Chinese biotech stocks rose against the trend, with WuXi Biologics up 3% and Sirnaomics up 13.4%. Technology stocks generally declined, with Baidu, Alibaba, Tencent, and others all experiencing losses. The United States allowed NVIDIA to sell H200 chips to China, leading to a decline in related chip stocks

    AASTOCKS·
    HK
    02257
    +0.48%
    US
    WXXWY
    +2.44%
    HK
    02269
    -0.30%
    AASTOCKS·
    HK
    02257
    +0.48%
    US
    WXXWY
    +2.44%
    HK
    02269
    -0.30%

    Sirnaomics Chairman Boosts Stake; Shares Jump 14%

    Sirnaomics Chairman Boosts Stake; Shares Jump 14%

    marketscreener·
    HK
    02257
    +0.48%
    marketscreener·
    HK
    02257
    +0.48%

    Sirnaomics Chairman Increases Stake, Signaling Confidence in Growth

    Sirnaomics Ltd.'s chairman, Dr. Poon Hung Fai, increased his stake by purchasing 100,000 shares at HK$6.83 each, raising his total shareholding to 16.44%. This move signals strong insider confidence in the company's growth prospects, potentially influencing investor sentiment positively. Sirnaomics focuses on RNAi therapeutics in the pharmaceutical industry. The latest analyst rating for its stock is Hold with a HK$7.50 price target.

    Tip Ranks·
    HK
    02257
    +0.48%
    Tip Ranks·
    HK
    02257
    +0.48%

    Sirnaomics Ltd. Completes Partial Share Subscription to Boost Drug Development

    Sirnaomics Ltd. completed a partial share subscription, issuing 1,003,700 new shares at HK$12.00 each, raising HK$12.0 million for drug development. The remaining shares were mutually terminated without affecting operations. The funds will enhance RNAi therapeutics. Current analyst rating is Hold with a HK$7.50 target. Sirnaomics focuses on RNAi therapeutics, including STP705 and STP122G. Market cap is HK$736.1M.

    Tip Ranks·
    HK
    02257
    +0.48%
    Tip Ranks·
    HK
    02257
    +0.48%

    17:31 ET Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight

    The basal cell carcinoma market is set for growth from 2025-2034, driven by new drug approvals and an expanding patient pool. Key emerging therapies include Remetinostat, STP705, SP-002, and LTX-315/VP-315. The market is expected to grow significantly in the US, EU4, UK, and Japan. Factors such as rising incidence, aging population, and technological advancements in treatment are contributing to this growth. Companies like Medvir, Sirnaomics, Stamford Pharmaceuticals, and Lytix Biopharma are leading the development of new therapies.

    prnewswire·
    HK
    02257
    +0.48%
    prnewswire·
    HK
    02257
    +0.48%
    © 2025 Longbridge｜Disclaimer